{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:25:50Z","timestamp":1770902750622,"version":"3.50.1"},"reference-count":15,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geriatrics"],"abstract":"<jats:p>The use of statins for primary prevention in older adults remains controversial. In this manuscript, we present a case of an 81-year-old woman with a history of HTN, HLD, Alzheimer\u2019s dementia and osteoporosis, who presented to a geriatrics clinic with profound muscle weakness accompanied by new functional deficits in the setting of taking double her prescribed dose of atorvastatin. She was admitted to the hospital where she was found to have rhabdomyolysis. Muscle biopsy and serologic work up revealed anti-HMG statin co-reductase myopathy as the cause of her symptoms. The patient was treated with steroids IVIG and immunomodulators with marked improvement in her weakness; however, her course was complicated by delirium and multiple falls, resulting in several fragility fractures. This case highlights the need to conduct a risk\u2013benefit analysis prior to initiating new therapies in patients with limited life expectancy, including the consideration of the potential for medication errors.<\/jats:p>","DOI":"10.3390\/geriatrics7020033","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:26:22Z","timestamp":1647811582000},"page":"33","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Ounce of Prevention, a Pound of Complications: A Case of Statin-Induced Necrotizing Myopathy in a Frail Elderly Patient"],"prefix":"10.3390","volume":"7","author":[{"given":"Oleg","family":"Stens","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California, San Diego, CA 92161, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Neutel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA 90502, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5229-1116","authenticated-orcid":false,"given":"Elizabeth L.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA 90502, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"ref_1","unstructured":"Saeed, A., and Mehta, L. (2020, December 27). Statin therapy in Older Adults for Primary Prevention of Atherosclerotic Cardiovascular Disease: The Balancing Act. Available online: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/10\/01\/11\/39\/statin-therapy-in-older-adults-for-primary-prevention-of-atherosclerotic-cv-disease."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force (2016). Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: U.S. Preventive Services Task Force Recommendation Statement. JAMA, 316, 1997\u20132007.","DOI":"10.1001\/jama.2016.15450"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jamainternmed.2017.1457","article-title":"Risks of Statin Therapy in Older Adults","volume":"177","author":"Curfman","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_4","first-page":"676","article-title":"Recognition and management of polymyalgia rheumatica and giant cell arteritis","volume":"88","author":"Caylor","year":"2013","journal-title":"Am. Fam. Physician"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-Associated Autoimmune Myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Cholesterol Treatment Trialists\u2019 Coalition. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Fulcher","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2020.7848","article-title":"Association of Satin Use with All-Cause Mortality in US Veterans 75 Years and Older","volume":"324","author":"Orkaby","year":"2020","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"k3359","DOI":"10.1136\/bmj.k3359","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: Retrospective cohort study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamainternmed.2017.1442","article-title":"Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT. Randomized Clinical Trial","volume":"177","author":"Han","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40266-019-00673-w","article-title":"Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines","volume":"36","author":"Hawley","year":"2019","journal-title":"Drugs Aging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jacc.2017.10.080","article-title":"Primary Prevention with Statins in the Elderly","volume":"71","author":"Mortensen","year":"2018","journal-title":"J Am. Coll. Cardiol."},{"key":"ref_13","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pds.1287","article-title":"Risk factors for statin-associated rhabdomyolysis","volume":"16","author":"Schech","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A Clinician\u2019s Guide to Statin Drug-Drug Interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J. Clin. Lipidol."}],"container-title":["Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3417\/7\/2\/33\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:38:45Z","timestamp":1760135925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3417\/7\/2\/33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["geriatrics7020033"],"URL":"https:\/\/doi.org\/10.3390\/geriatrics7020033","relation":{},"ISSN":["2308-3417"],"issn-type":[{"value":"2308-3417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]}}}